BOSTON, March 1, 2017 /PRNewswire/ -- BioDirection, Inc., a privately held medical device company developing novel and rapid point-of-care products for the objective detection and monitoring of traumatic brain injury (TBI), announced today that the company will participate in the International Brain Injury Association's 12th World Congress on Brain Injury to be held March 29 – April 1, 2017 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
Sergey Dryga, PhD, MBA, chief scientific officer of BioDirection, will present results from a pre-clinical study of the company's Tbit™ System for detection of TBI during the Neurotechnology in Rehabilitation session Friday, March 31st from 3:15-4:45pm CT in the Grand Chenier Room. In addition, BioDirection will present a poster titled, "Development of Silicon Nanowire Technology for Biomarker Testing."
"We are excited to be able to present the results of our human frozen serum sample study at the World Congress," said Dr. Dryga. "Participants in this conference include many of the leading clinicians in the field, allowing us to demonstrate the potential of the Tbit System to be used as a flexible and objective tool for diagnosing and monitoring brain injury."
The Tbit System is based on proprietary nanotechnology biosensors that are capable of providing rapid and accurate measurement of protein biomarkers released from the brain immediately following a head trauma. The company's first Tbit product utilizes a panel of two clinically-validated TBI biomarkers, S100 calcium binding protein B (S100β) and glial fibrillary acidic protein (GFAP). The flexible platform is fully scalable with multiplexing functionality, providing the ability to measure virtually any protein biomarker panel from whole blood. The Tbit System includes a disposable cartridge and portable analyzer capable of generating a test result in less than two minutes from a single drop of blood at the earliest stages of an injury.
The International Brain Injury Association's World Congress on Brain Injury is the largest gathering of international professionals working in the field of traumatic and acquired brain injury including stroke. For more information, visit http://ibia2017.org/.
About BioDirection, Inc.
BioDirection, Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the Tbit™ blood test, delivers rapid biologically-based results to accurately confirm a traumatic brain injury/concussion. BioDirection's platform system utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. To learn more about BioDirection visit http://www.biodirection.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biodirection-to-participate-in-12th-world-congress-on-brain-injury-300415810.html
SOURCE BioDirection, Inc.